SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NTEG- Bloodless Glucose Monitor
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Stratajema who wrote (27)9/23/1997 10:40:00 PM
From: DryHeat   of 176
 
This article seems to be a condensed version of the study. I have a hard copy of the Mayo Clinic study which I can fax as a way of thank you for all your research you published here. The interesting thing that I have found is that Integ has done some in house testing using the needle and their electronics to achive better results. The study although good had to many time lags and handling problems to truly simulate actual use. It does show viability though. With 95 % corelation being acceptable, and this study showing 97%. The 99% corelation shown in house is outstanding.
If the publishing of this study shows acceptance by the Diabetic Community it may be the cause for the rise in trading volume as of late. I look for the following in the next half year.
1. A manufacturing agreement for the electronics
2. FDA submission
3. A buyout by large biotech

This is what I hope. But lingering in the background is the depletion of funds in late 98. How they handle this is the million dollar question.

Thanks, Norbert
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News